San Francisco Health Official Asks FDA to Make Viagra Controlled Substance Because of Association With Higher STD Rates
August 24, 2004
A San Francisco public health official has petitioned FDA to make Pfizer's anti-impotence drug Viagra a controlled substance because of studies showing an association between use of the medication and higher rates of HIV and other sexually transmitted diseases, the San Francisco Chronicle reports. Dr. Jeffrey Klausner, director of STD prevention and control for the San Francisco Department of Public Health, has requested that Viagra and similar drugs be listed as Schedule III controlled substances -- a category of legal drugs that are often used for non-prescription uses, such as steroids. Schedule III drugs are easier to track and harder to prescribe because they require more detailed reporting from doctors. The petition, which was filed Aug. 4 and made public Monday, also requests that labels for Viagra and similar drugs include a warning that the drug is linked to an increased risk of STDs. Klausner has been in talks with FDA for two years but said he decided this month to address the issue formally by filing the citizen's petition with the approval of the public health department. "While the FDA was not actively opposed to a label change, they were not making any effort to do anything about it," Klausner said. Pfizer opposes the petition, according to the Chronicle.
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.